The Guardian has published an open callout asking readers who have taken GLP-1 receptor agonists — the drug class including semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro) — for a year or more to share their experiences of life before and after significant weight loss. The piece is not reporting. It is sourcing. The framing centers on identity disruption: how do people process rapid physical transformation when the world suddenly treats them differently? The Guardian cites research showing women in particular experience measurably better outcomes in dating and job-seeking after GLP-1-driven weight loss — an observation that says more about structural weight discrimination than about the drugs themselves. The 100-million-user figure is the buried lede. GLP-1 receptor agonists have scaled faster than almost any drug class in history, driven by Novo Nordisk's Ozempic/Wegovy and Eli Lilly's Mounjaro. Global revenues are projected to exceed $100 billion annually by 2030. The speed of adoption has outpaced longitudinal safety data, insurance coverage frameworks, and any societal reckoning with what mass pharmacological weight loss actually means. The Guardian's questions — about "before" and "after" selves, about workplace dynamics shifting, about romantic prospects changing — are pointed. They implicitly acknowledge that if losing weight transforms how institutions treat you, the problem was never the weight. It was the discrimination. GLP-1s don't fix bias; they let individuals buy their way past it, one $1,000-per-month injection at a time. This is a callout dressed as a story, and it reveals the editorial machinery: the Guardian needs first-person testimony to build a feature about the psychological costs of rapid weight loss. The real story — who profits from 100 million prescriptions, who can afford them, who bears the cost when supply is diverted from diabetics to weight-loss patients — is not being asked here. The piece contains no original reporting, no expert sourcing, and no data beyond a single global user figure and an unattributed research claim about women's dating and employment outcomes. It is, structurally, a form with a preamble. What it does do, inadvertently, is frame the central tension of the GLP-1 era: a drug that works extraordinarily well at the individual level may be papering over systemic failures — in healthcare access, in anti-fat discrimination, in how labor and romantic markets allocate value based on body size — rather than addressing them.
